TP53 and esophageal squamous cell carcinoma: Therefore, we believe mutp53 is a promising cancer-specific drug target, and targeting it with novel small-molecule compounds that can restore its function may open up new strategies for the clinical treatment of a wide variety of patients with p53-mutant cancer, containing those with ESCC.